Stockscreener 앱 받기
1.84
0.00%
0.00
전일 마감가:
$1.84
열려 있는:
$1.88
하루 거래량:
180.06K
Relative Volume:
0.76
시가총액:
$54.41M
수익:
$80.97M
순이익/손실:
$-78.31M
주가수익비율:
-0.166
EPS:
-11.0849
순현금흐름:
$-129.56M
1주 성능:
+0.55%
1개월 성능:
+0.55%
6개월 성능:
-15.98%
1년 성능:
-2.65%
1일 변동 폭
$1.80
$1.89
1주일 범위
$1.79
$1.959
52주 변동 폭
$1.325
$2.89
Fortress Biotech Inc Stock (FBIO) Company Profile
명칭
Fortress Biotech Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
FBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.84 | 54.11M | 80.97M | -78.31M | -129.56M | -11.08 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-15 | 재개 | ROTH MKM | Buy |
| 2022-08-04 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-02 | 개시 | The Benchmark Company | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2018-02-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
| 2017-03-22 | 개시 | JMP Securities | Mkt Outperform |
| 2016-10-03 | 개시 | ROTH Capital | Buy |
모두보기
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum - Yahoo Finance
Checkpoint Therapeutics, Inc.(NasdaqCM: CKPT) dropped from S&P TMI Index - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpo - GuruFocus
Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics - marketscreener.com
Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | FBIO Stock News - GuruFocus
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - GlobeNewswire
Fortress Biotech, Inc. Announces Acquisition of Checkpoint Therapeutics by Sun Pharmaceutical Industries Limited - Nasdaq
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - Benzinga
Fortress Biotech Cashes In: $28M Upfront Plus Royalties in Strategic Checkpoint Sale to Sun Pharma - Stock Titan
Checkpoint Therapeutics shareholders approve Sun Pharma merger By Investing.com - Investing.com India
One Fortress Biotech Insider Raised Stake By 26% In Previous Year - simplywall.st
Checkpoint Investor Sues for Info on Sale From Fortress to Sun - Bloomberg Law News
New Strong Sell Stocks for May 16th - The Globe and Mail
Q2 EPS Estimates for Fortress Biotech Raised by Roth Capital - Defense World
How the (FBIOP) price action is used to our Advantage - news.stocktradersdaily.com
Sun Pharma Q4 Consol Net PAT 21.5 Billion Rupees - marketscreener.com
Fortress Biotech Reports Q1 2025 Financial Highlights - TipRanks
Fortress Biotech First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fortress Biotech Inc (FBIO) Reports Q1 2025 Revenue of $13.1M, S - GuruFocus
Fortress Biotech: Q1 Earnings Snapshot - CT Insider
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Fortress Biotech, Inc. SEC 10-Q Report - TradingView
Fortress Biotech Inc (FBIO) Reports Q1 2025 Revenue of $13.1M, Surpassing Estimates - GuruFocus
Fortress Biotech Reports First Quarter 2025 Financial Results an - GuruFocus
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Earnings: Triple Win with $28M Checkpoint Deal, FDA Fast-Track, and Rosacea Drug Launch - Stock Titan
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Wednesday - Defense World
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Secures $416M Merger Deal After Landmark FDA Cancer Drug Approval - Stock Titan
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference | FBIO Stock News - GuruFocus
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference - The Manila Times
Renaissance Technologies LLC Has $356,000 Stock Holdings in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Fortress Biotech, Inc. (NASDAQ:FBIO) Stock Position Boosted by Envestnet Asset Management Inc. - Defense World
Geode Capital Management LLC Increases Stock Position in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease - The Globe and Mail
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - ADVFN
Sun Pharma shares in focus as co to acquire Checkpoint Therapeutics for $355 million - MSN
Fortress Biotech Board Member Resigns for New Role - TipRanks
When the Price of (FBIOP) Talks, People Listen - news.stocktradersdaily.com
Fortress Biotech (NASDAQ:FBIOP) Trading Down 2.1% – What’s Next? - Defense World
This Fortress Biotech Insider Increased Their Holding By 26% Last Year - Yahoo Finance
Roth Capital Forecasts Reduced Earnings for Fortress Biotech - Defense World
FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class ActionFBIO - MarketScreener
SEC Form POS AM filed by Fortress Biotech Inc. - Quantisnow
Journey Medical appoints new COO amid growth phase - Investing.com
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Fortress Biotech Inc (FBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.19%
자본화:
|
볼륨(24시간):